{{Rsnum
|rsid=3740057
|Gene=DNMBP
|Chromosome=10
|position=101658585
|Orientation=minus
|GMAF=0.3921
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 35.7 | 42.9 | 21.4
| HCB | 64.0 | 33.1 | 2.9
| JPT | 63.7 | 31.9 | 4.4
| YRI | 30.6 | 50.0 | 19.4
| ASW | 35.1 | 50.9 | 14.0
| CHB | 64.0 | 33.1 | 2.9
| CHD | 63.0 | 31.5 | 5.6
| GIH | 32.0 | 46.0 | 22.0
| LWK | 28.4 | 52.3 | 19.3
| MEX | 16.1 | 66.1 | 17.9
| MKK | 22.4 | 52.6 | 25.0
| TSI | 28.7 | 53.5 | 17.8
| HapMapRevision=28
}}[[rs3740057]] is one of 2 SNPs in the [[DNMBP]] gene that has been associated with increased risk for late-onset [[Alzheimer's disease]] in Belgian and Japanese populations; the other SNP being [[rs10883421]].{{PMID|18359537}}

{{PharmGKB
|RSID=rs3740057
|Name_s=
|Gene_s=DNMBP
|Feature=
|Evidence=PubMed ID:18359537
|Annotation=This variant is associated with Alzheimer dementia in the Belgian population
|Drugs=
|Drug Classes=
|Diseases=Alzheimer Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA161615750
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3740057
|overall_frequency_n=1517
|overall_frequency_d=3234
|overall_frequency=0.469079
|n_genomes=36
|n_genomes_annotated=0
|n_haplomes=43
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}